Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization o... Vertex Pharmaceuticals Incorporated is a leading biotechnology company founded in 1989 and headquartered in Boston, Massachusetts. It specializes in the discovery, development, and commercialization of transformative therapies, with a primary focus on cystic fibrosis (CF), a life-threatening genetic disease. The company markets a portfolio of CF treatments, including TRIKAFTA/KAFTRIO for patients aged 2 and older with at least one F508del mutation, ALYFTREK for those 6 years and older, SYMDEKO/SYMKEVI and ORKAMBI for patients 6 years and 1 year or older respectively, and KALYDECO for infants as young as 1 month with specific CF mutations. Vertex Pharmaceuticals Incorporated plays a pivotal role in the pharmaceuticals and biotech sector by addressing unmet needs in rare diseases through innovative small-molecule drugs. Its pipeline extends beyond CF into areas like acute and neuropathic pain, with candidates such as VX-548 advancing toward regulatory approval. With trailing twelve-month revenue of approximately $9.72 billion and a market capitalization around $86-101 billion, the company demonstrates significant financial strength and global market presence across multiple exchanges.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for Vertex Pharmaceuticals

We have not yet reviewed Vertex Pharmaceuticals's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Vertex Pharmaceuticals's data?

Start your 30-day free trial to request a data review for Vertex Pharmaceuticals.

Start Free Trial

Legal Center Contact Us